Better knowledge of new T-size descriptors in adjuvant chemotherapy effect needed Authors draw no particular recommendations because of size of studyThe latest analysis released in June’s Journal of Thoracic Oncology indicates there could be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected individuals with node bad non-small cell lung tumor. The scholarly study, released in the June 2012 problem of the International Association for the analysis of Lung Cancer’s Journal of Thoracic Oncology, analyzed the result of tumor size and KRAS mutations on survival reap the benefits of adjuvant platinum structured chemotherapy in sufferers with node adverse non-small cell lung malignancy. The objective of the retrospective research was to use the most up to date, 7th edition, TNM staging program, to a retrospective cohort of resected, node negative, non-little cell lung cancer individuals who had been treated with adjuvant platinum structured chemotherapy.Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan healthcare policy research company unaffiliated with Kaiser Permanente.. CDC says fluoride has no evidence of benefit for infants In a letter to California senator Barbara Boxer the Centers for Disease Control director Thomas Frieden responded to questions on the subject of fluoride and infants. The Institute of Medicine in 1997 arranged the adequate amount of fluoride for infants 0 to six months of age at .01 milligrams each day, which is the amount of fluoride found in breast milk. The CDC was asked if more fluoride than the adequate amount was beneficial. CDC director Frieden wrote We don’t realize data that straight answers your questions about the additional security from tooth decay that could derive from greater daily fluoride consumption by infants, 0-6 months of age.